The Next Horizon in Precision Oncology: Proteogenomics to Inform Cancer Diagnosis and Treatment

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2021 Apr 2

PMID 33798439

Citations 73

Authors

Henry Rodriguez

Jean Claude Zenklusen

Louis M Staudt

James H Doroshow

Douglas R Lowy

Affiliations

Soon will be listed here.

Abstract

When it comes to precision oncology, proteogenomics may provide better prospects to the clinical characterization of tumors, help make a more accurate diagnosis of cancer, and improve treatment for patients with cancer. This perspective describes the significant contributions of The Cancer Genome Atlas and the Clinical Proteomic Tumor Analysis Consortium to precision oncology and makes the case that proteogenomics needs to be fully integrated into clinical trials and patient care in order for precision oncology to deliver the right cancer treatment to the right patient at the right dose and at the right time.

Citing Articles

Proteogenomic characterisation of primary oral cancer unveils extracellular matrix remodelling and immunosuppressive microenvironment linked to lymph node metastasis.

Liu Y, Yang Z, Pu J, Zhong J, Khoo U, Su Y Clin Transl Med. 2025; 15(3):e70261.

PMID: 40038875 PMC: 11879901. DOI: 10.1002/ctm2.70261.

A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes.

Li Z, Chen L, Wei Z, Liu H, Zhang L, Huang F Front Immunol. 2025; 16:1518102.

PMID: 40018029 PMC: 11866059. DOI: 10.3389/fimmu.2025.1518102.

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.

Naru J, Othus M, Lin C, Biernacki M, Bleakley M, Chauncey T EJHaem. 2024; 5(6):1243-1251.

PMID: 39691254 PMC: 11647701. DOI: 10.1002/jha2.1041.

π-HuB: the proteomic navigator of the human body.

He F, Aebersold R, Baker M, Bian X, Bo X, Chan D Nature. 2024; 636(8042):322-331.

PMID: 39663494 DOI: 10.1038/s41586-024-08280-5.

A hypoxia-activated and microenvironment-remodeling nanoplatform for multifunctional imaging and potentiated immunotherapy of cancer.

Song J, Wang H, Meng X, Li W, Qi J Nat Commun. 2024; 15(1):10395.

PMID: 39613774 PMC: 11607447. DOI: 10.1038/s41467-024-53906-x.

References

Zhang B, Whiteaker J, Hoofnagle A, Baird G, Rodland K, Paulovich A . Clinical potential of mass spectrometry-based proteogenomics. Nat Rev Clin Oncol. 2018; 16(4):256-268. PMC: 6448780. DOI: 10.1038/s41571-018-0135-7. View

Mertins P, Mani D, Ruggles K, Gillette M, Clauser K, Wang P . Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016; 534(7605):55-62. PMC: 5102256. DOI: 10.1038/nature18003. View

Carr S, Abbatiello S, Ackermann B, Borchers C, Domon B, Deutsch E . Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics. 2014; 13(3):907-17. PMC: 3945918. DOI: 10.1074/mcp.M113.036095. View

Lange V, Picotti P, Domon B, Aebersold R . Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008; 4:222. PMC: 2583086. DOI: 10.1038/msb.2008.61. View

Doroshow D, Doroshow J . Genomics and the History of Precision Oncology. Surg Oncol Clin N Am. 2019; 29(1):35-49. PMC: 6878897. DOI: 10.1016/j.soc.2019.08.003. View

Lander E, Linton L, Birren B, Nusbaum C, Zody M, Baldwin J . Initial sequencing and analysis of the human genome. Nature. 2001; 409(6822):860-921. DOI: 10.1038/35057062. View

McClung N, Lewis R, Gargano J, Querec T, Unger E, Markowitz L . Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey. J Adolesc Health. 2019; 65(6):715-722. DOI: 10.1016/j.jadohealth.2019.07.003. View

Kandoth C, Schultz N, Cherniack A, Akbani R, Liu Y, Shen H . Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447):67-73. PMC: 3704730. DOI: 10.1038/nature12113. View

Kennedy J, Abbatiello S, Kim K, Yan P, Whiteaker J, Lin C . Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods. 2013; 11(2):149-55. PMC: 3922286. DOI: 10.1038/nmeth.2763. View

10.

Fiore L, Rodriguez H, Shriver C . Collaboration to Accelerate Proteogenomics Cancer Care: The Department of Veterans Affairs, Department of Defense, and the National Cancer Institute's Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) Network. Clin Pharmacol Ther. 2017; 101(5):619-621. DOI: 10.1002/cpt.658. View

11.

Flaherty K, Gray R, Chen A, Li S, Patton D, Hamilton S . The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020; 112(10):1021-1029. PMC: 7566320. DOI: 10.1093/jnci/djz245. View

12.

Tsai C, Zhao R, Williams S, Moore R, Schultz K, Chrisler W . An Improved Boosting to Amplify Signal with Isobaric Labeling (iBASIL) Strategy for Precise Quantitative Single-cell Proteomics. Mol Cell Proteomics. 2020; 19(5):828-838. PMC: 7196584. DOI: 10.1074/mcp.RA119.001857. View

13.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

14.

Grossman R, Heath A, Ferretti V, Varmus H, Lowy D, Kibbe W . Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 2016; 375(12):1109-12. PMC: 6309165. DOI: 10.1056/NEJMp1607591. View

15.

Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6. View

16.

Paulovich A, Billheimer D, Ham A, Vega-Montoto L, Rudnick P, Tabb D . Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics. 2009; 9(2):242-54. PMC: 2830837. DOI: 10.1074/mcp.M900222-MCP200. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Picotti P, Bodenmiller B, Aebersold R . Proteomics meets the scientific method. Nat Methods. 2012; 10(1):24-7. DOI: 10.1038/nmeth.2291. View

19.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

20.

Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D . Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell. 2020; 183(7):1962-1985.e31. PMC: 8143193. DOI: 10.1016/j.cell.2020.10.044. View